Trials / Completed
CompletedNCT00955981
Gout Dose Response Study
Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- Ardea Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare the proportion of subjects whose serum urate (sUA) level is \< 6.0 mg/dL after 28 days of dosing by treatment group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RDEA594 | Uricosuric agent for the treatment of gout |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-03-01
- Completion
- 2011-09-01
- First posted
- 2009-08-10
- Last updated
- 2014-03-07
Locations
29 sites across 7 countries: United States, Bulgaria, Canada, Czechia, Georgia, Germany, Poland
Source: ClinicalTrials.gov record NCT00955981. Inclusion in this directory is not an endorsement.